Patients’ Voices Largely Absent From FDA Reviews of New Cancer Drugs – Renal and Urology News
The FDA encourages collection and reporting of patient-reported outcomes (PROs) in clinical trials, but a substantial proportion of applications seeking product approval lack these data.